Skip to content
lifestyle.friendhood.net
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Tenaya Therapeutics, Inc.
Tenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
November 4, 2026
Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
September 14, 2026
Tenaya Therapeutics to Participate in Upcoming September Investor Conferences
September 3, 2026
Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
August 4, 2026
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
July 14, 2026
Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer
June 29, 2026